Gylvin Lykke Hinsch
CIK: 0002135139
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
PRQR
ProQR Therapeutics N.V.
Director
Discretionary Trading P&L
Holdings
About Hinsch Gylvin Lykke
Hinsch Gylvin Lykke (SEC CIK 0002135139) files insider reports with the SEC as Director of ProQR Therapeutics N.V. (PRQR).
Signal8 holds 2 ownership filings by Hinsch Gylvin Lykke (1 Form 3, 1 Form 4), filed between Jun 2, 2026 and Jun 3, 2026. Those filings report 1 transaction, the latest on Jun 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hinsch Gylvin Lykke's filings is in LEIDEN.
Recent filings by Hinsch Gylvin Lykke
- Jun 2, 2026: Grant or award of PRQR derivative securities (Form 4, code A).
Other insiders filing for ProQR Therapeutics N.V. (PRQR)
- de Boer Daniel Anton, Chief Executive Officer
- Filius Bart, Director
- Valerio Domenico, Director
- Platenburg Gerardus Johannes, Chief Scientific Officer
- Maier Martin Alexander, Director
- Lawton Alison Frances, Director